Personal information

Other IDs

Scopus Author ID: 56161955800

Countries

Denmark

Activities

Collapse all

Employment (2)

Herlev Hospital: Herlev , DK

2019-04-01 to present (National Center for Cancer Immune Therapy)
Employment
Source: Self-asserted source
Morten Holmström

Zealand University Hospital: Roskilde, DK

2014-10-01 to 2019-03-31 | Ph. D. student (Department of Hematology)
Employment
Source: Self-asserted source
Morten Holmström

Education and qualifications (1)

Copenhagen of Copenhagen: Copenhagen, DK

2004-09-01 to 2011-06-20 | MD
Education
Source: Self-asserted source
Morten Holmström

Works (28)

Non-myeloablative Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis. A Population-Based Study from Eastern Denmark

Transplantation and Cellular Therapy
2025-03 | Journal article
DOI: 10.1016/j.jtct.2025.03.006
Contributors: Morten Orebo Holmström; Lia Minculescu; Katrine Nørgaard; Brian Thomas Kornblit; Ida Schjødt; Marietta Nygaard; Niels Smedegaard Andersen; Henrik Sengeløv; Helle Bruunsgaard; Søren Lykke Petersen et al.
Source: check_circle
Crossref

The CALR mutations enhance the expression of the immunosuppressive proteins GARP and LAP on peripheral blood lymphocytes through increased binding of activated platelets

British Journal of Haematology
2024-08-20 | Journal article
DOI: 10.1111/bjh.19711
Contributors: Morten Orebo Holmström; Josephine Hallundbæk Ruders; Caroline Hasselbalch Riley; Morten Kranker Larsen; Jacob Handlos Grauslund; Lasse Kjær; Vibe Skov; Christina Ellervik; Belinda B. Guo; Matthew Linden et al.
Source: check_circle
Crossref

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

Journal for ImmunoTherapy of Cancer
2023-03 | Journal article
DOI: 10.1136/jitc-2022-006432
Contributors: Rasmus Erik Johansson Mortensen; Morten Orebo Holmström; Thomas Landkildehus Lisle; Jane P Hasselby; Gro L Willemoe; Özcan Met; Inge Marie Svane; Julia Johansen; Dorte L Nielsen; Inna M Chen et al.
Source: check_circle
Crossref

Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment

OncoImmunology
2022-12-31 | Journal article
DOI: 10.1080/2162402X.2022.2026020
Contributors: Simone Kloch Bendtsen; Maria Perez-Penco; Mie Linder Hübbe; Evelina Martinenaite; Morten Orebo Holmström; Stine Emilie Weis-Banke; Nicolai Grønne Dahlager Jørgensen; Mia Aaboe Jørgensen; Shamaila Munir Ahmad; Kasper Mølgaard Jensen et al.
Source: check_circle
Crossref

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Science Translational Medicine
2022-06-15 | Journal article
DOI: 10.1126/scitranslmed.aba4380
Contributors: Mathieu Gigoux; Morten O. Holmström; Roberta Zappasodi; Joseph J. Park; Stephane Pourpe; Cansu Cimen Bozkus; Levi M. B. Mangarin; David Redmond; Svena Verma; Sara Schad et al.
Source: check_circle
Crossref

Characterization of TGFβ-specific CD4+T cells through the modulation of TGFβ expression in malignant myeloid cells

Cellular & Molecular Immunology
2021-11-15 | Journal article
DOI: 10.1038/s41423-021-00770-0
Contributors: Rasmus Erik Johansson Mortensen; Morten Orebo Holmström; Mads Hald Andersen
Source: check_circle
Crossref

Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner

Cellular & Molecular Immunology
2021-02-06 | Journal article
DOI: 10.1038/s41423-020-00593-5
Contributors: Morten Orebo Holmström; Rasmus Erik Johansson Mortensen; Angelos Michail Pavlidis; Evelina Martinenaite; Stine Emilie Weis-Banke; Mia Aaboe-Jørgensen; Simone Kloch Bendtsen; Özcan Met; Ayako Wakatsuki Pedersen; Marco Donia et al.
Source: check_circle
Crossref

Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer

Cancer Immunology, Immunotherapy
2020-02-08 | Journal article
DOI: 10.1007/s00262-019-02473-y
Contributors: Morten Orebo Holmström; Sabrina Cordua; Vibe Skov; Lasse Kjær; Niels Pallisgaard; Christina Ellervik; Hans Carl Hasselbalch; Mads Hald Andersen
Source: check_circle
Crossref

The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines

OncoImmunology
2020-01 | Journal article
DOI: 10.1080/2162402X.2020.1771142
Contributors: Stine Emilie Weis-Banke; Mie Linder Hübbe; Morten Orebo Holmström; Mia Aaboe Jørgensen; Simone Kloch Bendtsen; Evelina Martinenaite; Marco Carretta; Inge Marie Svane; Niels Ødum; Ayako Wakatsuki Pedersen et al.
Source: check_circle
Crossref

Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy

Leukemia & Lymphoma
2019-11-10 | Journal article
DOI: 10.1080/10428194.2019.1633634
Contributors: Morten Orebo Holmström; Guy W. Novotny; Jesper Petersen; Mia Aaboe-Jørgensen; Hans Carl Hasselbalch; Mads H. Andersen; Signe Ledou Nielsen; Daniel El Fassi; Claudia Schöllkopf
Source: check_circle
Crossref

Neo-antigen specific memory T-cell responses in healthy individuals

OncoImmunology
2019-07-03 | Journal article
DOI: 10.1080/2162402X.2019.1599640
Contributors: Morten Orebo Holmström; Hans Carl Hasselbalch; Mads Hald Andersen
Source: check_circle
Crossref

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals

Blood Cancer Journal
2019-01-17 | Journal article
DOI: 10.1038/s41408-018-0166-4
Contributors: Morten O. Holmström; Shamaila M. Ahmad; Uffe Klausen; Simone K. Bendtsen; Evelina Martinenaite; Caroline H. Riley; Inge M. Svane; Lasse Kjær; Vibe Skov; Christina Ellervik et al.
Source: check_circle
Crossref

Cancer immune therapy for myeloid malignancies: present and future

Seminars in Immunopathology
2019-01-09 | Journal article
DOI: 10.1007/s00281-018-0693-x
Contributors: Morten Orebo Holmström; Hans Carl Hasselbalch
Source: check_circle
Crossref

Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation

OncoImmunology
2018-09-02 | Journal article
DOI: 10.1080/2162402X.2018.1468957
Contributors: Mia Aaboe Jørgensen; Morten Orebo Holmström; Evelina Martinenaite; Caroline Hasselbalch Riley; Hans Carl Hasselbalch; Mads Hald Andersen
Source: check_circle
Crossref

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

OncoImmunology
2018-06-03 | Journal article
DOI: 10.1080/2162402X.2018.1433521
Contributors: Morten Orebo Holmström; Caroline Hasselbalch Riley; Vibe Skov; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Source: check_circle
Crossref

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

OncoImmunology
2018-02 | Journal article
DOI: 10.1080/2162402X.2017.1390641
Contributors: Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard et al.
Source: check_circle
Crossref

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Leukemia & lymphoma
2017-08 | Journal article
DOI: 10.1080/10428194.2017.1359743
PMID: 28792253
Source: Self-asserted source
Morten Holmström via Europe PubMed Central

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Leukemia
2017-07 | Journal article
DOI: 10.1038/leu.2017.214
PMID: 28676668
Source: Self-asserted source
Morten Holmström via Europe PubMed Central

Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients.

2016 | Journal article
DOI: 10.3109/10428194.2015.1046867
PMID: 25936872
Contributors: Bjørn ME; Holmström MO; Hasselbalch HC
Source: Self-asserted source
Morten Holmström via Europe PubMed Central
grade
Preferred source (of 2)‎

The Danish national multiple myeloma registry

Clinical Epidemiology
2016 | Journal article
DOI: 10.2147/CLEP.S99463
EID:

2-s2.0-84995677656
Contributors: Gimsing, P.; Holmström, M.O.; Wirenfelt Klausen, T.; Frost Andersen, N.; Gregersen, H.; Pedersen, R.S.; Plesner, T.; Trøllund Pederse, P.; Frederiksen, M.; Frølund, U. et al.
Source: Self-asserted source
Morten Holmström via Scopus - Elsevier

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment

PLOS ONE
2016-10 | Journal article
DOI: 10.1371/journal.pone.0165336
Contributors: Lasse Kjær; Sabrina Cordua; Morten O. Holmström; Mads Thomassen; Torben A Kruse; Niels Pallisgaard; Thomas S. Larsen; Karin de Stricker; Vibe Skov; Hans C. Hasselbalch et al.
Source: Self-asserted source
Morten Holmström via Crossref Metadata Search
grade
Preferred source (of 2)‎

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

Leukemia
2016-10 | Journal article
DOI: 10.1038/leu.2016.290
Contributors: M O Holmström; M D Hjortsø; S M Ahmad; Ö Met; E Martinenaite; C Riley; P Straten; I M Svane; H C Hasselbalch; M H Andersen
Source: Self-asserted source
Morten Holmström via Crossref Metadata Search
grade
Preferred source (of 2)‎

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

2016-09 | Journal article
DOI: 10.1038/leu.2016.233
PMID: 27560107
Contributors: Holmström MO; Riley CH; Svane IM; Hasselbalch HC; Andersen MH
Source: Self-asserted source
Morten Holmström via Europe PubMed Central
grade
Preferred source (of 2)‎

[New disease markers within the chronic myeloproliferative neoplasms].

2015-05 | Journal article
PMID: 25967091
Contributors: Holmström MO; Ocias LF; Kallenbach K; Kjær L; Kristensen TK; Pallisgaard N; Petersen BL; Skov V; de Stricker K; Larsen TS et al.
Source: Self-asserted source
Morten Holmström via Europe PubMed Central

[Status and perspectives on chronic myeloproliferative neoplasm treatment].

2015-05 | Journal article
PMID: 25967090
Contributors: Ocias LF; Holmström MO; Riley CH; Andersen CL; Rønnov-Jessen D; Starklint J; Frederiksen M; Steffensen MS; Bjerrum OW; Farmer S et al.
Source: Self-asserted source
Morten Holmström via Europe PubMed Central

Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.

2015-04 | Journal article
DOI: 10.1002/ajh.23932
PMID: 25561348
Contributors: Holmström MO; Gimsing P; Abildgaard N; Andersen NF; Helleberg C; Clausen NA; Klausen TW; Frederiksen M; Kristensen DL; Larsen H et al.
Source: Self-asserted source
Morten Holmström via Europe PubMed Central
grade
Preferred source (of 2)‎

Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma.

2014-08 | Journal article
DOI: 10.1111/ejh.12353
PMID: 24766221
Contributors: Vangsted AJ; Klausen TW; Gimsing P; Abildgaard N; Andersen NF; Gang AO; Holmström M; Gregersen H; Vogel U; Schwarz P et al.
Source: Self-asserted source
Morten Holmström via Europe PubMed Central
grade
Preferred source (of 2)‎

[Pathology, diagnostics, and treatment of Waldenstrom's macroglobulinaemia].

2011-10 | Journal article
PMID: 21985832
Contributors: Holmström MO
Source: Self-asserted source
Morten Holmström via Europe PubMed Central

Peer review (1 review for 1 publication/grant)

Review activity for Springer seminars in immunopathology. (1)
How many people are using ORCID?